keyword
MENU ▼
Read by QxMD icon Read
search

HIV LIVER DISEASE

keyword
https://www.readbyqxmd.com/read/28329108/increased-mortality-among-persons-with-chronic-hepatitis-c-with-moderate-or-severe-liver-disease-a-cohort-study
#1
Javier A Cepeda, David L Thomas, Jacquie Astemborski, Mark S Sulkowski, Gregory D Kirk, Shruti H Mehta
Background: Despite the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, treatment is often denied until liver fibrosis has progressed to at least moderate fibrosis and in some cases cirrhosis. That practice is justified on assumptions that there are no medical consequences to having moderate disease and that disease stage transitions can be anticipated. Methods: We performed transient elastography on 964 people chronically infected with HCV with a history of injection drug use living in Baltimore, Maryland...
March 10, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28321877/pharmacological-interventions-for-acute-hepatitis-b-infection-an-attempted-network-meta-analysis
#2
REVIEW
Konstantinos Mantzoukis, Manuel Rodríguez-Perálvarez, Elena Buzzetti, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy
BACKGROUND: Infection with hepatitis B virus (HBV) can be symptomatic or asymptomatic. Apart from chronic HBV infection, the complications related to acute HBV infection are severe acute viral hepatitis and fulminant hepatitis characterised by liver failure. The optimal pharmacological treatment of acute HBV infection remains controversial. OBJECTIVES: To assess the benefits and harms of pharmacological interventions in the treatment of acute HBV infection through a network meta-analysis and to generate rankings of the available treatments according to their safety and efficacy...
March 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28306597/diagnosis-of-viral-hepatitis
#3
Philippa J Easterbrook, Teri Roberts, Anita Sands, Rosanna Peeling
PURPOSE OF REVIEW: Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and HIV-HBV and HCV coinfection are major causes of chronic liver disease worldwide. Testing and diagnosis is the gateway for access to both treatment and prevention services, but there remains a large burden of undiagnosed infection globally. We review the global epidemiology, key challenges in the current hepatitis testing response, new tools to support the hepatitis global response (2016-2020 Global Hepatitis Health Sector strategy, and 2017 WHO guidelines on hepatitis testing and their key recommendations) and future directions and innovations in hepatitis diagnostics...
March 16, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28298195/role-of-systemic-inflammation-scores-for-prediction-of-clinical-outcomes-in-patients-treated-with-atazanavir-not-boosted-by-ritonavir-in-the-italian-master-cohort
#4
Maria Concetta Postorino, Mattia Prosperi, Emanuele Focà, Eugenia Quiros-Roldan, Elisa Di Filippo, Franco Maggiolo, Alberto Borghetti, Nicoletta Ladisa, Massimo Di Pietro, Andrea Gori, Laura Sighinolfi, Angelo Pan, Nicola Mazzini, Carlo Torti
BACKGROUND: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy are unknown. METHODS: An observational study was carried out on the Italian MASTER, selecting HIV infected patients on cART switching to an uATV-containing regimen. Baseline was set as the last visit before uATV initiation. In the primary analysis, a composite clinical end-point was defined as the first occurring of any condition among: liver, cardiovascular, kidney, diabetes, non AIDS related cancer or death events...
March 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28296739/ugt1a1-28-relationship-with-abnormal-total-bilirubin-levels-in-chronic-hepatitis-c-patients-outcomes-from-a-case-control-study
#5
Marcelo Moreira Tavares de Souza, Victor Van Vaisberg, Rodrigo Martins Abreu, Aline Siqueira Ferreira, Camila daSilvaFerreira, Paulo Dominguez Nasser, Helena Scavone Paschoale, Flair José Carrilho, Suzane Kioko Ono
Gilbert syndrome (GS) is a frequent benign clinical condition, marked by intermittent unconjugated hyperbilirubinemia, mostly due to the polymorphism uridine diphosphate-glucuronosyltransferase 1A1*28 (UGT1A1*28). Hyperbilirubinemia has been reported in a GS patient undergoing hepatitis C treatment, and other UGT isoforms polymorphisms have been linked to worse outcomes in viral hepatitis. Yet, little is known to GS contributions' to the liver disease scenario. Our aim was to assess UGT1A1 genotypes' frequency in chronic hepatitis C (CHC) patients and correlate with total bilirubin (TB)...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28288014/the-times-they-are-a-changing-hope-for-hiv-to-hiv-organ-transplantation
#6
Ghady Haidar, Nina Singh
HIV-infected persons who achieve undetectable viral loads on antiretroviral therapy currently have near-normal lifespans. Liver disease is a major cause of non-AIDS-related deaths, and as a result of longer survival, the prevalence of end-stage renal disease in HIV is increasing. HIV-infected persons undergoing organ transplantation generally achieve comparable patient and graft survival rates compared to their HIV-uninfected counterparts, despite a nearly threefold increased risk of acute rejection. However, the ongoing shortage of suitable organs can limit transplantation as an option, and patients with HIV have higher waitlist mortality than others...
March 1, 2017: Transplantation
https://www.readbyqxmd.com/read/28284005/non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash-in-hiv
#7
REVIEW
Jürgen Kurt Rockstroh
Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection...
March 10, 2017: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/28281441/miliary-tuberculosis
#8
Surendra K Sharma, Alladi Mohan
Miliary tuberculosis (TB) results from a massive lymphohematogenous dissemination of Mycobacterium tuberculosis bacilli and is characterized by tiny tubercles evident on gross pathology resembling millet seeds in size and appearance. The global HIV/AIDS pandemic and widespread use of immunosuppressive drugs and biologicals have altered the epidemiology of miliary TB. Considered to be predominantly a disease of infants and children in the pre-antibiotic era, miliary TB is increasingly being encountered in adults as well...
March 2017: Microbiology Spectrum
https://www.readbyqxmd.com/read/28280398/interrelationship-of-hepatitis-c-virus-genotypes-with-patient-characteristics-in-bahrain
#9
Maheeba A Abdulla, Eman A Murad, Hend A Aljenaidi, Duha R Aljowder, Omar Ik Aljeeran, Eman Farid, Jehad R Al Qamish
AIM: Hepatitis C virus (HCV) shows genotype-based variation in prevalence across geographical regions. This study was conducted to understand the clinical interrelationship of HCV genotypes with patient characteristics. METHODS: Medical records of 122 patients positive for HCV RNA test collected during 2013 and 2014 were included for analysis. Only adults were included in the study. HCV RNA extraction and genotyping was done as part of the routine diagnostic requirements...
2017: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/28272163/real-world-efficacy-of-daclatasvir-and-sofosbuvir-with-and-without-ribavirin-in-hiv-hcv-co-infected-patients-with-advanced-liver-disease-in-a-french-early-access-cohort
#10
Karine Lacombe, Hélène Fontaine, Catherine Dhiver, Sophie Metivier, Eric Rosenthal, Teresa Antonini, Marc Antoine Valantin, Patrick Miailhes, Stanislas Harent, Dominique Batisse, Georges-Philippe Pageaux, Julie Chas, Hugues Aumaitre, Stephanie Dominguez, Thierry Allegre, Alain Lafeuillade, Eric Billaud, Pierre De Truchis, Philippe Perre, Vincent Leroy, Victor De Ledinghen, Philippe Sogni, Francois Dabis, Yue Zhao, Anne Filipovics, Larysa Fedchuk, Raoudha Akremi, Yacia Bennai, Dominique Salmon Ceron
BACKGROUND: Efficacious, well-tolerated direct antiviral agents have drastically changed the prognosis of hepatitis C virus (HCV) disease, but real-world data for oral treatments are limited in key populations such as human immunodeficiency virus (HIV)/HCV co-infection with advanced liver disease. Daclatasvir (DCV) efficacy and safety was assessed in the French "Autorisation Temporaire d'Utilisation" (ATU) program providing DCV ahead of market authorization to patients with advanced HCV disease without other treatment options...
March 6, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28263456/drug-drug-interactions-and-diagnostics-for-drug-users-with-hiv-and-hiv-hcv-coinfections-introduction
#11
Jag H Khalsa, Andrew H Talal, Gene Morse
Substance use and pharmacologic treatment of co-occurring infections such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are associated with many adverse consequences including pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs). The National Institute on Drug Abuse sponsored a 2-day conference on DDIs at which clinicians/scientists from government, academia, and the pharmaceutical industry presented the most current research findings to formulate a comprehensive overview of DDIs...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28262574/health-adjusted-life-expectancy-in-hiv-positive-and-hiv-negative-men-and-women-in-british-columbia-canada-a-population-based-observational-cohort-study
#12
Robert S Hogg, Oghenowede Eyawo, Alexandra B Collins, Wendy Zhang, Shahab Jabbari, Mark W Hull, Viviane Dias Lima, Tareq Ahmed, Claire E Kendall, Keri N Althoff, Amy C Justice, Rolando Barrios, Jeannie Shoveller, Julio S G Montaner
BACKGROUND: We sought to understand whether people living with HIV (PLHIV) ever on highly active antiretroviral therapy (ART) follow a pattern where morbidity is compressed into the last years of life or lessened as people age. We aimed to estimate health-adjusted life expectancy (HALE) among adults living with and without HIV, and examine dependency between causes of comorbidities. METHODS: The Comparative Outcomes and Service Utilization Trends (COAST) study is a retrospective cohort of adults (≥20 years) including all known PLHIV and a 10% random sample of the general population of British Columbia, and with longitudinal data spanning from April 1, 1996, to Dec 31, 2012...
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28262573/liver-disease-and-healthy-life-expectancy-with-hiv
#13
Hugo Perazzo, Paula M Luz
No abstract text is available yet for this article.
March 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28261385/influence-of-vitamin-d-on-liver-fibrosis-in-chronic-hepatitis-c-a-systematic-review-and-meta-analysis-of-the-pooled-clinical-trials-data
#14
Alia S Dadabhai, Behnam Saberi, Katie Lobner, Russell T Shinohara, Gerard E Mullin
AIM: To investigate the relationship between vitamin D and liver fibrosis in hepatitis C-monoinfected or hepatitis C virus (HCV)-human immunodeficiency virus (HIV) co-infected patients. METHODS: Pertinent studies were located by a library literature search in PubMed/Embase/Cochrane/Scopus/LILACS by two individual reviewers. Inclusion criteria: (1) studies with patients with HCV or co-infected HCV/HIV; (2) studies with patients ≥ 18 years old; (3) studies that evaluated liver fibrosis stage, only based on liver biopsy; and (4) studies that reported serum or plasma 25(OH)D levels...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28261380/adverse-effects-of-oral-antiviral-therapy-in-chronic-hepatitis-b
#15
REVIEW
Bircan Kayaaslan, Rahmet Guner
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class adverse effects (i.e., myopathy, neuropathy, lactic acidosis) and dissimilar adverse effects. All NAs carry a "Black Box" warning because of the potential risk for mitochondrial dysfunction...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28259653/deciphering-molecular-properties-and-docking-studies-of-hepatitis-c-and-non-hepatitis-c-antiviral-inhibitors-a-computational-approach
#16
Arthi Venkatesan, J Febin Prabhu Dass
BACKGROUND: Hepatitis C is an infectious liver disease with high mortality rate which is caused by Hepatitis C virus. Several treatment methods have been applied to combat this deadly virus including interferons, vaccine and direct acting antivirals (DAAs). However, the later shows promising effects in HCV treatment with lower adverse effect. Specifically, the DAAs target the non-structural proteins (NS3 and NS5B). PURPOSE: The objective of the present study is to hypothesize an alternative antiviral inhibitor for HCV from the available other antivirals...
March 1, 2017: Life Sciences
https://www.readbyqxmd.com/read/28252527/soluble-cd163-predicts-incident-chronic-lung-kidney-and-liver-disease-in-hiv-infection
#17
Ditte M Kirkegaard-Klitbo, Niels Mejer, Troels B Knudsen, Holger J Møller, Søren K Moestrup, Susanne D Nielsen, Gitte Kronborg, Thomas Benfield
OBJECTIVE: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma soluble CD163 (sCD163) and incident non-AIDS comorbidities in well-treated HIV-infected individuals. DESIGN: Prospective single-center cohort study. METHODS: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/05 and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision (ICD-10) diagnosis codes and registry linkage in 2014/2015...
March 1, 2017: AIDS
https://www.readbyqxmd.com/read/28250664/potential-of-cannabidiol-for-the-treatment-of-viral-hepatitis
#18
Henry I C Lowe, Ngeh J Toyang, Wayne McLaughlin
Viral hepatitis B (HBV) and hepatitis C (HCV) pose a major health problem globally and if untreated, both viruses lead to severe liver damage resulting in liver cirrhosis and cancer. While HBV has a vaccine, HCV has none at the moment. The risk of drug resistance, combined with the high cost of current therapies, makes it a necessity for cost-effective therapeutics to be discovered and developed. The recent surge in interest in Medical Cannabis has led to interest in evaluating and validating the therapeutic potentials of Cannabis and its metabolites against various diseases including viruses...
January 2017: Pharmacognosy Research
https://www.readbyqxmd.com/read/28249574/reactivation-of-occult-hbv-infection-in-an-hiv-hcv-co-infected-patient-successfully-treated-with-sofosbuvir-ledipasvir-a-case-report-and-review-of-the-literature
#19
Gabriele Fabbri, Ilaria Mastrorosa, Alessandra Vergori, Valentina Mazzotta, Carmela Pinnetti, Susanna Grisetti, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori
BACKGROUND: Reactivation of occult or inactive Hepatitis B virus (HBV) infection during immunosuppressant treatments is well known and widely described in literature. The same observation has been made in Hepatitis C (HCV)-infected patients previously exposed to HBV and treated with interferon-free DAA treatments. Because of common transmission routes, persons may have been exposed to HCV, HBV and HIV, but few cases have been reported in this scenario to date. Frequency of HBV reactivation in HIV/HCV co-infected patients previously exposed to HBV and treated with DAA remains unclear...
March 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28241797/changes-in-mortality-rates-and-causes-of-death-in-a-population-based-cohort-of-persons-living-with-and-without-hiv-from-1996-to-2012
#20
Oghenowede Eyawo, Conrado Franco-Villalobos, Mark W Hull, Adriana Nohpal, Hasina Samji, Paul Sereda, Viviane D Lima, Jeannie Shoveller, David Moore, Julio S G Montaner, Robert S Hogg
BACKGROUND: Non-HIV/AIDS-related diseases are gaining prominence as important causes of morbidity and mortality among people living with HIV. The purpose of this study was to characterize and compare changes over time in mortality rates and causes of death among a population-based cohort of persons living with and without HIV in British Columbia (BC), Canada. METHODS: We analysed data from the Comparative Outcomes And Service Utilization Trends (COAST) study; a retrospective population-based study created via linkage between the BC Centre for Excellence in HIV/AIDS and Population Data BC, and containing data for HIV-infected individuals and the general population of BC, respectively...
February 27, 2017: BMC Infectious Diseases
keyword
keyword
91330
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"